| Page 16 | Aplastic Anemia and MDS International Foundation (AAMDSIF)

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria

Author(s): 
Scheinberg P, Clé DV, Kim JS, Nur E, Yenerel MN, Barcellini W, Bonito D, Giai V, Hus M, Lee Y, Lekue CB, Panse J, Ueda Y, Buatois S, Gentile B, Kiialainen A, Patel H, Sreckovic S, Uguen M, Edwards J, Nagy Z, Kulasekararaj AG
Primary Author: 
Scheinberg P
Journal Title: 
American Journal of Hematology
Original Publication Date: 
Sep 2024

Crovalimab, a novel C5 inhibitor, allows for low-volume, every-4- week, subcutaneous self-administration. COMMODORE 1 (NCT04432584) is a phase 3, global, randomized trial evaluating crovalimab versus eculizumab in C5 inhibitor-experienced patients with

Bone Marrow Disease(s): 

The effect of hetrombopag combined with conventional treatment on immune function and quality of life in patients with severe aplastic anemia

Author(s): 
Chen WT, Wang SW, Huang Y, Tang RM, Liu D, Wang GY
Primary Author: 
Chen WT
Journal Title: 
Annals of Hematology
Original Publication Date: 
Sep 2024

This study aimed to investigate the effect of hetrombopag combined with conventional treatment on immune function in patients with severe

Bone Marrow Disease(s): 

Modified Delphi panel consensus recommendations for management of severe aplastic anemia

Author(s): 
Babushok DV, DeZern AE, de Castro CM, Rogers ZR, Beenhouwer D, Broder MS, Fanning SR, Gibbs SN, Hanna R, Maciejewski JP, Scott BL, Tantravahi SK, Wlodarski MW, Yermilov I, Patel BJ
Primary Author: 
Babushok DV
Journal Title: 
Blood Advances
Original Publication Date: 
Aug 2024

Severe

Bone Marrow Disease(s): 

Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations

Author(s): 
Shimano KA, Rothman JA, Allen SW, Castillo P, de Jong JLO, Dror Y, Geddis AE, Lau BW, McGuinn C, Narla A, Overholt K, Pereda MA, Sharathkumar A, Sasa G, Nakano TA, Myers K, Gloude NJ, Broglie L, Boklan J
Primary Author: 
Shimano KA
Journal Title: 
Pediatric Blood Cancer
Original Publication Date: 
Aug 2024

Severe

Bone Marrow Disease(s): 

Treatment of relapsed/refractory severe aplastic anemia in children: Evidence-based recommendations

Author(s): 
Shimano KA, Sasa G, Broglie L, Gloude NJ, Myers K, Nakano TA, Sharathkumar A, Rothman JA, Pereda MA, Overholt K, Narla A, McGuinn C, Lau BW, Geddis AE, Dror Y, de Jong JLO, Castillo P, Allen SW, Boklan J
Primary Author: 
Shimano KA
Journal Title: 
Pediatric Blood Cancer
Original Publication Date: 
Aug 2024

Severe

Bone Marrow Disease(s): 

Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia

Author(s): 
Connor MP, Prathapa N, Frey NV, Gill SI, Hexner EO, Bruno XJ, Lai CE, Loren AW, Luger SM, Matthews AH, McCurdy SR, Perl AE, Porter DL, Zeringue A, Oved JH, Olson TS, Pratz KW, Babushok DV
Primary Author: 
Connor MP
Journal Title: 
Haematologica
Original Publication Date: 
Aug 2024
Bone Marrow Disease(s):